Verastem Inc. (VSTM)

3.31
NASDAQ : Health Technology
Prev Close 3.23
Day Low/High 3.20 / 3.33
52 Wk Low/High 1.11 / 5.71
Avg Volume 966.60K
Exchange NASDAQ
Shares Outstanding 48.37M
Market Cap 154.29M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem Presents Preclinical Data At ASCO-SITC Highlighting The Synergistic Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Verastem Presents Preclinical Data At ASCO-SITC Highlighting The Synergistic Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that a poster highlighting the synergistic effects of duvelisib in...

Verastem Announces Increased Hercules Debt Facility

Verastem Announces Increased Hercules Debt Facility

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with...

Verastem Appoints Joseph Lobacki As Chief Commercial Officer

Verastem Appoints Joseph Lobacki As Chief Commercial Officer

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and...

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

First Week Of February 2018 Options Trading For Verastem (VSTM)

First Week Of February 2018 Options Trading For Verastem (VSTM)

Investors in Verastem Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new February 2018 contracts and identified the following put contract of particular interest.

Verastem Announces Pricing Of Public Offering Of Common Stock

Verastem Announces Pricing Of Public Offering Of Common Stock

Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its previously announced underwritten public...

Verastem Announces Public Offering Of Common Stock

Verastem Announces Public Offering Of Common Stock

Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that it intends to offer and sell $25 million of its common stock in...

Verastem Announces The Presentation Of Phase 1 Duvelisib Combination Data In T-Cell Lymphomas At The ASH 2017 Annual Meeting

Verastem Announces The Presentation Of Phase 1 Duvelisib Combination Data In T-Cell Lymphomas At The ASH 2017 Annual Meeting

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of new preclinical and Phase 1 clinical data from...

Verastem Announces Clinical Data From The Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival In Relapsed Or Refractory Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Verastem Announces Clinical Data From The Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival In Relapsed Or Refractory Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of the results from the Phase 3 DUO study...

Verastem To Present Results From Pivotal Phase 3 DUO Study In Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At A Research And Development Event At ASH 2017

Verastem To Present Results From Pivotal Phase 3 DUO Study In Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At A Research And Development Event At ASH 2017

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, will present clinical data from the Phase 3 DUO study evaluating the efficacy and...

Verastem To Present At Upcoming Investor Conferences

Verastem To Present At Upcoming Investor Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor...

Verastem Reports Third Quarter 2017 Financial Results

Verastem Reports Third Quarter 2017 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September 30, 2017 and...

Verastem Announces Data From Phase 3 DUO Study Selected For Oral Presentation At The American Society Of Hematology 2017 Annual Meeting

Verastem Announces Data From Phase 3 DUO Study Selected For Oral Presentation At The American Society Of Hematology 2017 Annual Meeting

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that four abstracts have been selected for presentation, including...

Verastem Announces Regulatory Strategy For Duvelisib New Drug Application Following Guidance From FDA

Verastem Announces Regulatory Strategy For Duvelisib New Drug Application Following Guidance From FDA

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of patients with cancer, today announced that a meeting was held with the U.

Verastem Pays Milestone Payment To Infinity Pharmaceuticals

Verastem Pays Milestone Payment To Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc.

Verastem Appoints NgocDiep Le, MD, PhD As Chief Medical Officer

Verastem Appoints NgocDiep Le, MD, PhD As Chief Medical Officer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of NgocDiep Le, MD, PhD, as Chief Medical Officer.

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.

Verastem To Present At The Cantor Fitzgerald Global Healthcare Conference

Verastem To Present At The Cantor Fitzgerald Global Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25 th at...

First Week Of VSTM November 17th Options Trading

First Week Of VSTM November 17th Options Trading

Investors in Verastem Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Verastem Reaches Analyst Target Price

In recent trading, shares of Verastem Inc have crossed above the average analyst 12-month target price of $4.62, changing hands for $4.92/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Verastem Shares Are Exploding 50% -- Here's Why

Verastem Shares Are Exploding 50% -- Here's Why

The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Verastem Expands Duvelisib Development Program To Include Peripheral T-Cell Lymphoma

Verastem Expands Duvelisib Development Program To Include Peripheral T-Cell Lymphoma

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the expansion of its duvelisib development program to include...

Verastem Announces Positive Top-line Data From The Pivotal Phase 3 DUO™ Study In Relapsed Or Refractory Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Verastem Announces Positive Top-line Data From The Pivotal Phase 3 DUO™ Study In Relapsed Or Refractory Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the...

Verastem Reports Second Quarter 2017 Financial Results

Verastem Reports Second Quarter 2017 Financial Results

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the second quarter ended June 30, 2017 and...

Verastem Publishes Scientific Data Highlighting Potential Role Of FAK Inhibition In Pancreatic And Breast Cancer

Verastem Publishes Scientific Data Highlighting Potential Role Of FAK Inhibition In Pancreatic And Breast Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced scientific findings from studies evaluating focal adhesion kinase...

Verastem Names Julie B. Feder As Chief Financial Officer

Verastem Names Julie B. Feder As Chief Financial Officer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Julie B.

Verastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib In Patients With Double-Refractory Follicular Lymphoma And Small Lymphocytic Lymphoma At The 22nd Congress Of The European Hematology Association

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of long-term follow-up data from the DYNAMO™...